JPS5936629B2 - 1,3-disubstituted-2-imidazolidines - Google Patents

1,3-disubstituted-2-imidazolidines

Info

Publication number
JPS5936629B2
JPS5936629B2 JP1208176A JP1208176A JPS5936629B2 JP S5936629 B2 JPS5936629 B2 JP S5936629B2 JP 1208176 A JP1208176 A JP 1208176A JP 1208176 A JP1208176 A JP 1208176A JP S5936629 B2 JPS5936629 B2 JP S5936629B2
Authority
JP
Japan
Prior art keywords
group
imino
formula
atom
benzhydryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP1208176A
Other languages
Japanese (ja)
Other versions
JPS5295665A (en
Inventor
文義 石川
雍史 安孫子
欣也 亀田
信悦 小野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP1208176A priority Critical patent/JPS5936629B2/en
Publication of JPS5295665A publication Critical patent/JPS5295665A/en
Publication of JPS5936629B2 publication Critical patent/JPS5936629B2/en
Expired legal-status Critical Current

Links

Description

【発明の詳細な説明】 本発明は一般式(I) □CH−響−C−R3(I) R。[Detailed description of the invention] The present invention relates to general formula (I) □CH-Hibiki-C-R3(I) R.

Y11 (式中R、は水素原子、低級アルキル基、低級アルコキ
シ基、ヒドロキシ基又はハロゲン原子を、R2は水素原
子又はフェニル基を、R3は低級アルキル基、低級アル
コキシ基、アミノ基又は低級アルキルアミノ基を、Yは
酸素原子、硫黄原子又はイミノ基を意味す)で示される
新規化合物1・3−ジ置換−2−イミノイミダゾリジン
又はその酸付加塩に関し、式(I)の化合物は強力な血
糖降下作用を呈する。
Y11 (In the formula, R is a hydrogen atom, a lower alkyl group, a lower alkoxy group, a hydroxy group, or a halogen atom, R2 is a hydrogen atom or a phenyl group, and R3 is a lower alkyl group, a lower alkoxy group, an amino group, or a lower alkylamino group. 1,3-disubstituted-2-iminoimidazolidine or its acid addition salt, the compound of formula (I) has a strong Exhibits a hypoglycemic effect.

式1)の化合物は下記の方法で製することが出来る。The compound of formula 1) can be produced by the following method.

(上記式中Qは酸素原子又はイミノ基を、Xはハロゲン
原子を、R4は低級アルキル基を、zは酸素原子又は硫
黄原子を、R5は低級アルキル基又は低級アルコキシ基
を、Mはアルカリ金属原子を意味し、R1及びR2は前
記に同じ)即ち、4法によれば式(3)で表わされるア
ミン類を水酸化ナトリウム等の塩基の存在下シアン化ハ
ロゲンと水溶液中反応させてもよいが、さらに有利には
式(9)の化合物の塩酸塩をシアン酸カリウムと熱時反
応させてベンズヒドリル一又はベンジル−アミノエチル
尿素としたのちシアン化ハロゲンと反応させた方がよい
(In the above formula, Q is an oxygen atom or an imino group, X is a halogen atom, R4 is a lower alkyl group, z is an oxygen atom or a sulfur atom, R5 is a lower alkyl group or a lower alkoxy group, M is an alkali metal In other words, according to Method 4, an amine represented by formula (3) may be reacted with a halogen cyanide in the presence of a base such as sodium hydroxide in an aqueous solution. However, it is more advantageous to react the hydrochloride of the compound of formula (9) hot with potassium cyanate to give benzhydryl mono- or benzyl-aminoethyl urea and then to react with the halogen cyanide.

又式(3)の化合物とS−メチルイソチオ尿素・硫酸塩
とを反応させて得られる成績体とシアン化ハロゲンとを
反応させてもえられる。8法によれば、式(1!)の原
料化合物のハロゲン化水素酸塩をシアン酸カリウム又は
シアン酸ナトリウムとジメチルスルホキシド中室温にて
反応させればよい。
It can also be obtained by reacting a product obtained by reacting the compound of formula (3) with S-methylisothiourea sulfate and a halogen cyanide. According to Method 8, the hydrohalide salt of the starting compound of formula (1!) may be reacted with potassium cyanate or sodium cyanate in dimethyl sulfoxide at room temperature.

ここで用いられる原料化合物例えば1ーベンジル−2−
イミノ−イミダゾリジン臭化水素酸塩はベンジルアミノ
エチルアミンをシアン化臭素のベンゼン溶液中へ添加反
応させることによつて定量的に得ることができる。8法
によれば、式(代)の化合物をチオシアン化硅素とベン
ゼン、クロロホルム等の不活性溶媒中約50〜80℃に
加熱すればよい。
The raw material compound used here, for example, 1-benzyl-2-
Imino-imidazolidine hydrobromide can be obtained quantitatively by adding benzylaminoethylamine to a benzene solution of bromine cyanide. According to Method 8, a compound of formula (sub) may be heated to about 50 to 80° C. in silicon thiocyanide and an inert solvent such as benzene or chloroform.

又式(代)の化合物とアルキルイソシアナート又はアル
キルイソチオシアナートをメタノール、エタノール等の
アルコール類或はクロロホルム、ベンゼン等の不活性溶
媒中室温〜約100℃に加熱することによつても目的化
合物を得ることが出来る。更には又、式(代)の化合物
とハロゲン化アセチル又は塩化メトキシカルボニル等を
クロロホルム、ベンゼン、ジメチルホルムアミド等の不
活性溶媒中、好ましくは水素化ナトリウム、トリエチル
アミン等の脱酸剤の存在下o℃〜室温で反応させてもよ
い。
The target compound can also be obtained by heating the compound of formula (2) and an alkyl isocyanate or an alkyl isothiocyanate in an alcohol such as methanol or ethanol or an inert solvent such as chloroform or benzene from room temperature to about 100°C. can be obtained. Furthermore, the compound of formula (2) and acetyl halide or methoxycarbonyl chloride may be mixed at o°C in an inert solvent such as chloroform, benzene or dimethylformamide, preferably in the presence of a deoxidizing agent such as sodium hydride or triethylamine. ~The reaction may be carried out at room temperature.

又?法は?法の変法であり、溶媒として低級アルコール
を用いるものであり、例えばN−ベンジルアミノエチレ
ンジアミンとシアン化臭素をメタノール中反応させると
1−ベンジル−2−イミノ− 3 −(1−メトキシ−
1−イミノ)メチルイミダゾリジンを得ることが出来る
or? What is the law? This is a modification of the method and uses a lower alcohol as a solvent. For example, when N-benzylaminoethylenediamine and bromine cyanide are reacted in methanol, 1-benzyl-2-imino-3-(1-methoxy-
1-imino)methylimidazolidine can be obtained.

かくして製される本発明の化合物は、イミダゾリジン環
の1・3位に前述の如き置換基を有するものであり、従
来の血糖降下薬とは根本的に異なる構造上の特異性を有
し、かつ強力な血糖降下作用を有するものである。
The compound of the present invention thus produced has the above-mentioned substituents at the 1st and 3rd positions of the imidazolidine ring, and has structural specificity that is fundamentally different from that of conventional hypoglycemic drugs. It also has a strong hypoglycemic effect.

更に詳しくは、本発明の化合物は正常な空腹動物に於て
、従来繁用されている血糖降下薬であるスルホニル尿素
系及びビグアニド系化合物と比較検討した結果より優れ
た効果を呈する。
More specifically, the compounds of the present invention exhibit superior effects in normal fasting animals compared to sulfonylurea and biguanide compounds, which are conventionally frequently used hypoglycemic drugs.

本発明化合物の数例についてその血糖降下作用を市販の
トルブタマイド及びフエンフオルミンと対比したときの
結果を下記に示す。方法8による製造例 実施例 1 1−ベンジルアミノ−2−アミノエタン塩酸塩1.86
yとシアン酸カリウム0.88yを混和ジメチルスルホ
キシド8m1中100〜110℃に1時間加熱する。
The results of comparing the hypoglycemic effects of several examples of the compounds of the present invention with those of commercially available tolbutamide and fenformin are shown below. Preparation Example by Method 8 Example 1 1-benzylamino-2-aminoethane hydrochloride 1.86
y and 0.88 y of potassium cyanate in 8 ml of dimethyl sulfoxide are heated to 100-110 DEG C. for 1 hour.

反応後減圧乾固し、残査に水50ゴ、水酸化ナトリウム
0.8yを加えて溶解し、シアン化臭素1.5yを加え
る。室温で攪拌していると1−ベンジル−2−イミノ−
3−カルバモイルイミダゾリジンの結晶が析出して来る
から30分後濾取、よく水洗、乾燥する。同一の方法で
表2に示す化合物を得た。
After the reaction, the mixture was dried under reduced pressure, and 50 g of water and 0.8 y of sodium hydroxide were added to dissolve the residue, and 1.5 y of bromine cyanide was added. When stirring at room temperature, 1-benzyl-2-imino-
Crystals of 3-carbamoylimidazolidine begin to precipitate, and after 30 minutes, they are collected by filtration, thoroughly washed with water, and dried. The compounds shown in Table 2 were obtained in the same manner.

実施例 62 実施例5で得られた1−(p−メトキシベンジル)−2
−イミノ−3−カルバモイルイミダゾリジン3.0Pを
メチレンクロリド150dに懸濁し、−50〜−60′
C,IIC.冷却する。
Example 62 1-(p-methoxybenzyl)-2 obtained in Example 5
-Imino-3-carbamoylimidazolidine 3.0P was suspended in methylene chloride 150d, -50 to -60'
C, IIC. Cooling.

ここへ三臭化ホウ素9.0fを加える。徐々に室温に上
昇せしめ、一夜攪拌を続ける。次いで氷水1001Rt
に注加し、水層を分取し、水酸化ナトリウムでアルカリ
性とした後、クロロホルムでよく洗浄し、未反応の原料
を除く。残つた水層を再び塩酸でPH3としてから減圧
濃縮すると結晶が析出して来るから瀘取する。これを水
307711に温時溶解し、ダウエツクス2X8(クロ
ール型)75m1のカラムに流して精製する。流出液を
集めて減圧濃縮すると1−(p−ヒドロキシベンジル)
−2−イミノ−3−カルバモイルイミダゾリジンの塩酸
塩が2.25f7(70%)得られる。融点203〜5
℃。実施例 7 1−ベンジルアミノ−2−グアニジノエタン硫酸塩4.
8fを1規定一水酸化ナトリウム60dに加えて溶解し
、シアン化臭素2.3Vを加える。
Add 9.0f of boron tribromide to this. Gradually warm to room temperature and continue stirring overnight. Then ice water 1001Rt
The aqueous layer is separated, made alkaline with sodium hydroxide, and thoroughly washed with chloroform to remove unreacted raw materials. The remaining aqueous layer is again adjusted to pH 3 with hydrochloric acid and then concentrated under reduced pressure to precipitate crystals, which are then filtered off. This was dissolved in 307711 water at a warm temperature, and purified by passing it through a 75 ml column of Dowex 2×8 (Kroll type). The effluent was collected and concentrated under reduced pressure to yield 1-(p-hydroxybenzyl).
2.25f7 (70%) of the hydrochloride of -2-imino-3-carbamoylimidazolidine is obtained. Melting point 203-5
℃. Example 7 1-Benzylamino-2-guanidinoethane sulfate 4.
Add and dissolve 8f in 60d of 1N sodium monohydroxide, and add 2.3V of bromine cyanide.

1時間室温で攪拌後、析出して来る結晶を瀘取し、これ
を50m1の熱水で処理して不溶物を瀘別後、減圧濃縮
し、粗結晶1.507をうる。
After stirring at room temperature for 1 hour, the precipitated crystals were collected by filtration, treated with 50 ml of hot water to remove insoluble materials, and concentrated under reduced pressure to obtain 1.507 g of crude crystals.

これをメタノールに溶解し、濃塩酸を加えてPH4とし
て減圧濃縮乾固すると1−ベンジル−2−イミノーアミ
ジノイミダゾリジン塩酸塩が得られた。融点178〜1
79℃方法5による製造例 1−ベンジル−2−イミノイミダゾリジン塩酸塩0.8
4yとシアン酸カリウム0.32Vをジメチルスルホキ
シド4mιに加えて溶解し、室温で4時間攪拌する。
This was dissolved in methanol, concentrated hydrochloric acid was added to adjust the pH to 4, and the solution was concentrated to dryness under reduced pressure to obtain 1-benzyl-2-iminoamidinoimidazolidine hydrochloride. Melting point 178-1
Preparation Example 1-Benzyl-2-iminoimidazolidine hydrochloride 0.8 by 79°C Method 5
4y and 0.32V of potassium cyanate were added and dissolved in 4ml of dimethyl sulfoxide, and the mixture was stirred at room temperature for 4 hours.

濃塩酸0.5mI1を加えて液性をPH3としたのち減
圧下にジメチルスルホキシドを除去する。残査に水を加
えて水酸化ナトリウムでアルカリ性としたのちクロロホ
ルムで抽出し、水洗、乾燥後クロロホルムを留去すると
1−ベンジルー2−イミノ−3−カルバモイルイミダゾ
リジンが得られる。方法?による製造例 実施例 9 シリコンテトライソチオシアナート0.90Vを乾燥ベ
ンゼン30ゴに溶解し、ここへ1−ベンジル−2−イミ
ノ−イミダゾリジン2.10tを加えシ※45分攪拌す
る。
After adding 0.5 ml of concentrated hydrochloric acid to adjust the pH to 3, dimethyl sulfoxide was removed under reduced pressure. Water is added to the residue, made alkaline with sodium hydroxide, extracted with chloroform, washed with water, dried, and then chloroform is distilled off to obtain 1-benzy-2-imino-3-carbamoylimidazolidine. Method? Example 9 Silicon tetraisothiocyanate (0.90 V) was dissolved in 30 g of dry benzene, 2.10 g of 1-benzyl-2-imino-imidazolidine was added thereto, and the mixture was stirred for 45 minutes.

減圧下に濃縮乾固し、10%含水−イソプロパノール2
0m1を加えてから10分加熱攪拌する。その後減圧濃
縮乾固し、残査にクロロホルム30m1を加えて不溶分
を濾別し、クロ》 口ホルム層はよく水洗したのち乾燥
、クロロホルムを留去すると1−ベンジル−2−イミノ
−3−チオカルバモイルイミダゾリジン0.24Vが得
られた。融点147〜148℃。以下同様の反応にて表
3に示す化合物を得た。
Concentrate to dryness under reduced pressure and add 10% water-isopropanol 2
After adding 0ml, heat and stir for 10 minutes. After that, it was concentrated to dryness under reduced pressure, 30 ml of chloroform was added to the residue, and the insoluble matter was filtered out. 0.24 V of carbamoylimidazolidine was obtained. Melting point 147-148°C. The compounds shown in Table 3 were obtained by the same reaction.

Claims (1)

【特許請求の範囲】 1 ▲数式、化学式、表等があります▼ (式中R_1は水素原子、低級アルキル基、低級アルコ
キシ基、ヒドロキシ基又はハロゲン原子を、R_2は水
素原子又はフェニル基を、R_3はアルキル基、アルコ
キシ基、アミノ基又はアルキルアミノ基を、Yは酸素原
子、硫黄原子又はイミノ基を意味す)で示される1・3
−ジ置換−2−イミノイミダゾリジン類又はその酸付加
塩。 2 1−ベンズヒドリル−2−イミノ−3−カルバモイ
ルイミダゾリジンである特許請求の範囲第1項記載の化
合物。 3 1−ベンズヒドリル−2−イミノ−3−アセチルイ
ミダゾリジンである特許請求の範囲第1項記載の化合物
。 4 1−ベンズヒドリル−2−イミノ−3−メトキシカ
ルボニルイミダゾリジンである特許請求の範囲第1項記
載の化合物。
[Claims] 1 ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In the formula, R_1 is a hydrogen atom, a lower alkyl group, a lower alkoxy group, a hydroxy group, or a halogen atom, R_2 is a hydrogen atom or a phenyl group, R_3 represents an alkyl group, an alkoxy group, an amino group, or an alkylamino group, and Y represents an oxygen atom, a sulfur atom, or an imino group).
-Disubstituted-2-iminoimidazolidines or acid addition salts thereof. 2. The compound according to claim 1, which is 1-benzhydryl-2-imino-3-carbamoylimidazolidine. 3. The compound according to claim 1, which is 1-benzhydryl-2-imino-3-acetylimidazolidine. 4. The compound according to claim 1, which is 1-benzhydryl-2-imino-3-methoxycarbonylimidazolidine.
JP1208176A 1976-02-06 1976-02-06 1,3-disubstituted-2-imidazolidines Expired JPS5936629B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1208176A JPS5936629B2 (en) 1976-02-06 1976-02-06 1,3-disubstituted-2-imidazolidines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1208176A JPS5936629B2 (en) 1976-02-06 1976-02-06 1,3-disubstituted-2-imidazolidines

Publications (2)

Publication Number Publication Date
JPS5295665A JPS5295665A (en) 1977-08-11
JPS5936629B2 true JPS5936629B2 (en) 1984-09-05

Family

ID=11795623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1208176A Expired JPS5936629B2 (en) 1976-02-06 1976-02-06 1,3-disubstituted-2-imidazolidines

Country Status (1)

Country Link
JP (1) JPS5936629B2 (en)

Also Published As

Publication number Publication date
JPS5295665A (en) 1977-08-11

Similar Documents

Publication Publication Date Title
EP2215050B1 (en) Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts
JPS6327462A (en) Manufacture of o-substituted hydroxylamine
JPS6053027B2 (en) Tetrazole derivative
JPS5922711B2 (en) Method for producing benzoxazolinone derivatives
JP2668816B2 (en) Process for producing benzothiadiazole derivative
JPS5936629B2 (en) 1,3-disubstituted-2-imidazolidines
JPS5949221B2 (en) Method for producing 3-acylamino-4-homoisotwistane
JPH0558985A (en) Production of cyanoguanidine derivative
JPS6360969A (en) Production of imidazole derivative
JPS5942359A (en) Preparation of sulfone
CA1059131A (en) Preparation of n-2-(6-hydroxybenzothiazolyl)-n-phenyl (or substituted phenyl) ureas
JPS607987B2 (en) Hydantoin derivatives
JPH0217163A (en) Production of diaminomaleonitrile and diaminoacrylonitrile derivative
JPS6261966A (en) Propionamidine derivatives and manufacture
US2430051A (en) Soluble sulfanilamide derivatives and process of preparing them
JPH02124868A (en) Production of n-sulfamil- propionamidine derivative
JPH04139170A (en) Substituted pyridinesufonylcarbamate-based compound, its production and production of substituted pyridinesulfonamide-based compound
JPS596865B2 (en) 5-((2-halogeno-1-hydroxy)alkyl) carbostyril
KR800001133B1 (en) Process for preparing 5-sulfamoyl benzoic acid substituted by heterocyclic compound
CA1122219A (en) Sulfur-containing benzimidazole derivatives, process for the preparation thereof and intermediates useful in production of the same
US2364593A (en) N, n'-diarylamidines
JPS6052158B2 (en) Cephalosporin compounds
JPS63208565A (en) Production of guanidine derivative
JPS5993060A (en) Preparation of cytosines
JPS6127961A (en) Preparation of n-substituted phthalimide